Cart
0

Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain - Barre Syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD: Global Opportunity Analysis and Industry Forecast, 2016 - 2022

Get 20% Free Customization In This Report
LI_16325
Pages: 220
Dec 2017 | 7792 Views
 
Author's : Onkar Sumant and Tenzin Kunsel
Tables: 37
Charts: 29
 

Intravenous Immunoglobulin (IVIG) Market Overview:

The Global Intravenous Immunoglobulin (IVIG) Market was valued at $7,861 million in 2015 and is projected to reach $12,632 million by 2022, registering a CAGR of 7.1% from 2016 to 2022. Immunoglobulins (IGs) are glycoproteins produced by plasma cells in response to antigens, which are considered as foreign bodies in a host system. They are highly complex entities that exhibit high specificity in their action. IGs are obtained from blood by fractionation process, and eventually purified for use in therapeutic and non-therapeutic applications. Various classes of immunoglobulin including IgG, IgA, and IgM are used for the treatment of immunological and neurological diseases.

Get more information on this report : Request Sample Pages

The major factors that drive the growth of the IVIG market include increase in geriatric population, surge in the number of hemophilic patients, rise in production of immunoglobulin due to the emergence of advanced technologies, and advent of enhanced purification techniques for better plasma yield. Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and others are expected to boost the market growth. However, stringent government regulations toward IVIG products and high risk of side effects associated with the use of IVIG are expected to hamper the growth of the market. On the contrary, technological advancements in IVIG products are expected to provide lucrative opportunities to the market in near future.

Get more information on this report : Request Sample Pages

Application segment review

Based on application, the global IVIG market is divided into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain‐Barre syndrome, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2015 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the significant increase in prevalence of hypogammaglobulinemia disorder across the globe. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally.

Get more information on this report : Request Sample Pages

Geography segment review

Based on region, the IVIG market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the largest contributor toward the global market, followed by Asia-Pacific. The presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth. However, LAMEA is projected to register the highest growth rate during the forecast period.

The report provides extensive competitive analysis and profiles of key market players that include Baxter International Inc.; CSL Ltd., Grifols, S.A.; Octapharma AG; Kedrion Biopharma Inc.; LFB Group; Biotest AG; China Biologics Products, Inc.; Shire (Baxalta); and Bayer AG.

The other players in the value chain include Hualan Biological Engineering Inc.; Omrix Biopharmaceuticals Ltd.; Behring GmbH; Shanghai RAAS Blood Products Co., Ltd.; Option Care Enterprises, Inc.; ADMA Biologics, Inc.; and BioScrip, Inc.

Key Benefits for Intravenous Immunoglobulin (IVIG) Market:

  • The report provides an in-depth analysis of the global IVIG market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
  • The report provides a detailed quantitative analysis of the industry from 2016 to 2022 to assist stakeholders to capitalize on the prevailing market opportunities.
  • An extensive analysis of the key segments of the industry helps understand the trends in the global IVIG market.
  • Key players and their strategies are provided to understand the competitive outlook of the industry.

Intravenous Immunoglobulin (IVIG) Key Market Segments:

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Immunodeficiency Disease
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain‐Barre Syndrome
  • Others

By Type

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Austria
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Africa
    • Middle East
 

Chapter: 1. INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. KEY BENEFITS FOR STAKEHOLDERS:

1.3. KEY MARKET SEGMENTS:

1.4. RESEARCH METHODOLOGY

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst tools and models

Chapter: 2. EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. OVERVIEW OF IVIG

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS

3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS

3.5. KEY FINDINGS

3.5.1. Top Factors Impacting global IVIG market

3.5.2. Top Investment Pockets Global IVIG Market

3.6. PORTERS FIVE FORCES ANALYSIS

3.6.1. Bargaining power of buyers (Low)

3.6.2. Bargaining power of suppliers (Low)

3.6.3. Threat of new entrants (low)

3.6.4. Threat of substitutes (low)

3.6.5. Intense competitive rivalry (moderate)

3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities

3.7.2. Support Activities

3.8. MARKET SHARE ANALYSIS (2014)

3.9. PRODUCT SCENARIO IN IVIG MARKET

3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS


3.10.1. IVIG regulations in United States and Europe

3.10.2. Reimbursements Scenario

3.11. INDICATIONS FOR IVIG

3.11.1. USFDA Indications

3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1

3.12.2. IgG2

3.12.3. IgG3

3.12.4. IgG4

3.13. CLINICAL TRIALS

3.15. MARKET DYNAMICS

3.15.1. Drivers

3.15.2. Restraints

3.15.3. Opportunities

Chapter: 4. IVIG MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CIDP

4.3.1. Market size and forecast

4.4. IMMUNODEFICIENCY DISEASES

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. PRIMARY ITP

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. SAD

4.9.1. Market size and forecast

4.10. GBS

4.10.1. Market size and forecast

4.11. OTHERS

4.11.1. Market size and forecast

Chapter: 5. IVIG MARKET BY PRODUCT TYPES

5.1. IGG

5.1.1. Key Market Trends

5.1.2. Clinical Interpretations

5.2. IGA

5.2.1. Key Market Trends

5.2.2. Clinical interpretation

5.3. IGM

5.3.1. Key Market Trends

5.3.2. Clinical Interpretation

5.4. IGE

5.4.1. Key Market Trends

5.4.2. Clinical Interpretation

5.5. IMMUNOGLOBULIN D (IGD)

5.5.1. Key Market Trends

Chapter: 6. IVIG MARKET, BY GEOGRAPHY

6.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. U.S.

6.2.1.1. U.S. Market size and forecast

6.2.2. Canada

6.2.2.1. Market size and forecast

6.2.3. Mexico

6.2.3.1. Market Size and forecast

6.3. EUROPE

6.3.1. Key market trends

6.3.2. Market size and forecast

6.3.3. U.K.

6.3.3.1. Market size and forecast

6.3.4. France

6.3.4.1. Market size and forecast

6.3.5. Germany

6.3.5.1. Market size and forecast

6.3.6. Italy

6.3.6.1. Market size and forecast

6.3.7. Austria

6.3.7.1. Market size and forecast

6.3.8. Russia

6.3.8.1. Market size and forecast

6.3.9. Other countries

6.3.9.1. Market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends

6.4.2. Market size and forecast

6.4.3. Australia

6.4.3.1. Market size and forecast

6.4.4. China

6.4.4.1. Market size and forecast

6.4.5. Japan

6.4.5.1. Market size and forecast

6.4.6. India

6.4.6.1. Market size and forecast

6.4.7. Others

6.4.7.1. Market size and forecast

6.5. LAMEA

6.5.1. Key Market Trends

6.5.2. Market size and forecast

6.5.3. Latin America

6.5.3.1. Market size and forecast

6.5.4. Africa

6.5.4.1. Market size and forecast

6.5.5. Middle East

6.5.5.1. Market size and forecast

Chapter: 7. COMPANY PROFILES

7.1. BIOTEST AG

7.1.1. Company Overview

7.1.2. Biotest AG: Company Snapshot

7.1.3. Operating business segments

7.1.4. Business performance

7.1.5. Key Strategic Moves & Developments

7.2. OCTAPHARMA AG

7.2.1. Company Overview

7.2.2. Octapharma AG: Company Snapshot

7.2.3. Operating business segments

7.2.4. Business performance

7.2.5. Key Strategic Moves & Developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Company Overview

7.3.2. Baxter International, Inc.: Company Snapshot

7.3.3. Operating business segments

7.3.4. Business performance

7.3.5. Key Strategic Moves & Developments

7.4. LFB BIOTECHNOLOGIES

7.4.1. Company Overview

7.4.2. LFB Biotechnologies: Company Snapshot

7.4.3. Operating business segments

7.4.4. Business performance

7.4.5. Key Strategic Moves & Developments

7.5. CHINA BIOLOGICS PRODUCTS INC.

7.5.1. Company overview

7.5.2. China Biologic Products Inc. Snapshot

7.5.3. Operating business segment overview

7.5.4. Financial performance

7.5.5. Key Strategic Moves & Developments

7.6. GRIFOLS S.A.

7.6.1. Company overview

7.6.2. Grifols S.A Snapshot

7.6.3. Operating Business Segment Overview

7.6.4. Financial performance

7.6.5. Strategic moves and developments

7.7. KEDRION BIOPHARMA

7.7.1. Company overview

7.7.2. Kedrion Biopharma. Snapshot

7.7.3. Operating business segment overview

7.7.4. Financial performance

7.7.5. Strategic moves and developments

7.8. CSL BEHRING

7.8.1. Company overview

7.8.2. CSL Behring Snapshot

7.8.3. Operating business segment overview

7.8.4. Financial performance

7.8.5. Strategic moves and developments

7.9. BDI PHARMA INC.

7.9.1. Company overview

7.9.2. BDI pharma Inc. Snapshot

7.9.3. Operating business segment overview

7.9.4. Strategic moves and developments

7.10. BAYER HEALTHCARE

7.10.1. Company overview

7.10.2. Business performance

7.10.3. Strategic moves and developments

LIST OF TABLES

TABLE 1. IVIG PRODUCTS COMMERCIALIZED IN MARKET

TABLE 2. USFDA INDICATIONS FOR IVIG

TABLE 3. EMA APPROVED INDICATIONS FOR IVIG

TABLE 4. IGG SUBCLASS

TABLE 5. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS

TABLE 6. DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY

TABLE 7. CLINICAL TRIALS FOR IVIG (2011-2014)

TABLE 8. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022,($MILLION)

TABLE 9. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022, (TON)

TABLE 10. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS

TABLE 11. HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 12. CIDP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 13. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY

TABLE 14. IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 15. MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 16. MMN IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 17. ITP TREATMENT OPTIONS

TABLE 18. ITP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 19. INFLAMMATORY MYOPATHIES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 20. SAD IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 21. GBS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 22. OTHER IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022

TABLE 23. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, ($MILLION)

TABLE 24. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, (TON)

TABLE 25. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)

TABLE 26. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)

TABLE 27. U.S. IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 28. CANADA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 29. MEXICO IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 30. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)

TABLE 31. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, (TON)

TABLE 32. U.K. IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 33. FRANCE IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 34. GERMANY IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 35. ITALY IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 36. AUSTRIA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 37. RUSSIA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 38. OTHER IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 39. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, ($MILLION)

TABLE 40. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, (TON)

TABLE 41. AUSTRALIA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 42. CHINA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 43. JAPAN IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 44. INDIA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 45. OTHER IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 46. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)

TABLE 47. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)

TABLE 48. LATIN AMERICA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 49. AFRICA IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 50. MIDDLE EAST IVIG MARKET ($MILLION & TON), 2014-2022

TABLE 51. OPERATING BUSINESS SEGMENT OVERVIEW

TABLE 52. OPERATING BUSINESS SEGMENT OVERVIEW

TABLE 53. CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT

TABLE 54. CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW

TABLE 55. GRIFOLS S.A SNAPSHOT

TABLE 56. GRIFOLS S.A OPERATING SEGEMENTS

TABLE 57. KEDRION INC. SNAPSHOT

TABLE 58. KEDRION BIOPHARMA OPERATING SEGMENTS

TABLE 59. CSL BEHRING SNAPSHOT

TABLE 60. CSL BEHRING OPERATING SEGMENTS

TABLE 61. BDI PHARMA INC SNAPSHOT

TABLE 62. BDIPHARMA OPERATING SEGMENTS

TABLE 63. BAYER HEALTHCARE COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY

FIGURE 2. TOP FACTORS IMPACTING GLOBAL IVIG MARKET (20152021)

FIGURE 3. TOP INVESTMENT POCKETSGLOBAL IVIG MARKET

FIGURE 4. PORTERS FIVE FORCES ANALYSIS

FIGURE 5. VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET

FIGURE 6. MARKET SHARE ANALYSISGLOBAL IVIG MARKET 2014

FIGURE 7. BIOTEST AG: REVENUE, 2013-2015, ($MILLION)

FIGURE 8. BIOTEST AG: REVENUE, BY SEGMENT, 2015 (%)

FIGURE 9. BIOTEST AG: REVENUE, BY GEOGRAPHY, 2015 (%)

FIGURE 10. OCTAPHARMA AG:REVENUE, 2013-2015, ($MILLION)

FIGURE 11. BAXTER INTERNATIONAL, INC.:REVENUE, 2013-2015, ($MILLION)

FIGURE 12. BAXTER INTERNATIONAL, INC.:REVENUE, BY BUSINESS SEGMENT, 2015 (%)

FIGURE 13. BAXTER INTERNATIONAL, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)

FIGURE 14. LFB BIOTECHNOLOGIES: REVENUE, 2013-2015, ($MILLION)

FIGURE 15. LFB BIOTECHNOLOGIES: REVENUE, BY BUSINESS SEGMENT, 2015 (%)

FIGURE 16. LFB BIOTECHNOLOGIES: REVENUE, BY GEOGRAPHY, 2015 (%)

FIGURE 17. CHINA BIOLOGIC PRODUCTS INC: REVENUE, 2013-2015, ($MILLION)

FIGURE 18. CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE, BY SEGMENTS, (2015)

FIGURE 19. GRIFOLS S.A: REVENUE, 2013-2015, ($MILLION)

FIGURE 20. FINANCIAL OF GRIFOLS S.A, BY GEOGRAPHY, (2015)

FIGURE 21. FINANCIAL GRIFOLS S.A., BY PRODUCT GROUPS, (2015)

FIGURE 22. KEDRION BIOPHARMA: REVENUE, 2013-2015, ($MILLION)

FIGURE 23. FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2015)

FIGURE 24. CSL BEHRING: REVENUE, 2013-2015, ($MILLION)

FIGURE 25. CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)

FIGURE 26. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)

FIGURE 26. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)

FIGURE 27. FINANCIAL REVENUE OF BAYER HEALTHCARE 2013-2015

FIGURE 28. FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2015

FIGURE 29. FINANCIALS OF BAYER HEALTHCARE, BY REGIONS, 2015

 

Intravenous immunoglobulin (IVIG) is used in the treatment of deficiency disorders such as hypogammaglobulinemia, Kawasaki disease, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Rise in immunoglobulin deficiency, and associated disorders drives the use of IVIG in clinical settings globally. GAMUNEX-C, Flebogamma DIF 5% & 10%, Gammaplex, and Kiovig are the key regulated products approved for use in therapy settings. There are several “off-label” products available in the market, which include Gammagard Liquid intravenous, Gammagard S/D intravenous, and Bivigam intravenous.

Recently, a paradigm shift has been observed in the development of subcutaneous immunoglobulin therapy, which limits the focus on development of IVIG-based products. Sub-cutaneous immunoglobulin formulations offer additional advantages for patients in terms of ease of administration, which has boosted their adoption in home settings. The IVIG market is an oligopolistic market, as it is dominated by prominent players like Grifols, CSL Behring, Baxter International, and Octapharma. In addition, these companies have a strong hold in the blood fractionation industry, and hence play a key role in determining the cost of blood product commodities such as albumin, fibrinogen, and other plasma entities.

The administration of immunoglobulin is the highest in North America, owing to the increase in adoption of immunoglobulin products, high awareness regarding the benefits of using immunoglobulin therapies among healthcare providers, and increase in disposable income among patients. Although the use of immunoglobulin in LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, surge in healthcare expenditure, and government initiative to enhance the healthcare departments. These factors contribute toward the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Intravenous Immunoglobulin (IVIG) Market

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4565
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5160
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $6747
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo